Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

RecruitingOBSERVATIONAL
Enrollment

220

Participants

Timeline

Start Date

August 9, 2007

Primary Completion Date

July 20, 2032

Study Completion Date

July 20, 2033

Conditions
Alpha-1 Antitrypsin DeficiencyAAT DeficiencyAATDCystic Fibrosis (CF)
Interventions
PROCEDURE

History and physical exam.

At every study visit, participant's will be asked about their medical history and will have a physical exam.

PROCEDURE

Blood draw.

At each study visit, participants will have an intravenous catheter (IV) placed in one of their veins and blood will be drawn from the IV for study testing.

PROCEDURE

Pulmonary function testing.

At every study visit, participants will have their lung function assessed. This is done by blowing forcefully at least 3 times into a tube. Testing will be done two times; before and after the use of an Albuterol inhaler.

DRUG

Albuterol inhaler.

At every study visit, participating subjects will take 2 puffs of an Albuterol inhaler after the first set of PFTs, but before the second set of PFTs. There will be at least a 30 minute period after the use of the Albuterol inhaler and the second set of PFTs.

Trial Locations (1)

32610

RECRUITING

Shands at the University of Florida, Gainesville

All Listed Sponsors
lead

University of Florida

OTHER